Collegium Pharmaceutical Inc (NASDAQ: COLL) has reported earnings for its first fiscal quarter (ending March 31) of $0.86 versus a loss $-0.51 for the same period a year ago. Relative to the consensus estimate of $1.60, this was a shortfall of $-0.74. For the latest four quarters through March 31, E.P.S. were $2.84 compared to $-0.86 a year ago.
Recent Price Action
Collegium Pharmaceutical Inc (NASDAQ: COLL) stock closed at $37.86 on 5/9/24 after a slight decline of -0.5%. Trading volume in this decline was normal. The stock is unchanged during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
COLL is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Collegium Pharmaceutical has a current Value Trend Rating of A (Highest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Collegium Pharmaceutical has a very high Appreciation Score of 93 and a very high Power Rating of 96, producing the Highest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment